Grant: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
University of Ottawa
$97,900.00
AI for drug design – chemical synthesis
FY 2021-22 · 2022-03-31
Summary
Designing a drug to treat a specific disease type is a highly challenging exercise due to breadth of the molecular search space and having a limited understanding about many diseases of interest. The successful discovery of a medicine for a target disease (gene/protein/pathway) usually takes many years and is associated with a very significant investment by private pharmaceutical organization, which in turn tends to result in an unaffordable price of medicines in the Canadian and global markets. The emergence of significant biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provides an unprecedented opportunity for automatic design of new drugs at a much faster pace and at a much lower cost, igniting hopes to discover drugs for diseases where no medicines currently exist. In this project researchers will aim to develop a data and AI-driven drug design platform/pipeline for precise and effective treatment of cancers and complex diseases.
Department
Program
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Recipient
Location
Ottawa|Ottawa, Ontario, Canada
Recipient Type
Academia
Business Number
119278877
Type
Grant
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2022-03-31 | 2021-22 | $97,900.00 |
| 1 | 2022-03-31 | 2021-22 | $97,900.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreement has been modified by 365 days.
Additional Information (French)
Cet accord a été modifié 1 fois. La date de fin du présent accord a été changé de 365 jours.
Agreement End Date
2024-03-31
Agreement Number
988469
Agreement Start Date
2022-03-31
Agreement Title
AI for drug design – chemical synthesis
Agreement Title (French)
L’IA au service de la création de médicaments — Synthèse de composés chimiques
Agreement Type
Grant
Agreement Value
$97,900.00
Amendment Date
2023-03-21
Amendment Number
1
Description
Designing a drug to treat a specific disease type is a highly challenging exercise due to breadth of the molecular search space and having a limited understanding about many diseases of interest. The successful discovery of a medicine for a target disease (gene/protein/pathway) usually takes many years and is associated with a very significant investment by private pharmaceutical organization, which in turn tends to result in an unaffordable price of medicines in the Canadian and global markets. The emergence of significant biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provides an unprecedented opportunity for automatic design of new drugs at a much faster pace and at a much lower cost, igniting hopes to discover drugs for diseases where no medicines currently exist. In this project researchers will aim to develop a data and AI-driven drug design platform/pipeline for precise and effective treatment of cancers and complex diseases.
Description (French)
Concevoir un médicament pour soigner une maladie précise est un exercice de haute voltige en raison des innombrables molécules parmi lesquelles il faut chercher et de nos connaissances restreintes sur beaucoup de maladies dignes d’intérêt. Habituellement, de nombreuses années s’écoulent avant qu’on trouve un remède pour une maladie quelconque (gène, protéine et voie d’administration) et les sociétés pharmaceutiques y engloutissent passablement d’argent, d’où le prix exorbitant des médicaments sur le marché canadien ou mondial. L’avènement de techniques d’acquisition massive et rapide de données biochimiques et génomiques et l’avancée des nouveaux paradigmes en intelligence artificielle offrent l’occasion unique : celle de concevoir automatiquement de nouveaux médicaments à un rythme beaucoup plus rapide et à bien moindre coût, ce qui alimente l’espoir que l’on découvre un traitement pour des maladies jugées jusqu’à présent incurables. Le projet vise l’élaboration d’une plateforme et d’un protocole de conception de médicaments fondés sur l’usage des données et l’intelligence artificielle en vue de trouver un traitement précis et efficace contre les cancers et les maladies complexes.
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Federal Riding
Ottawa–Vanier
Federal Riding (French)
Ottawa–Vanier
Federal Riding Number
35078
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Recipient Business Number
119278877
Recipient City
Ottawa|Ottawa
Recipient Country
CA
Recipient Legal Name
University of Ottawa
Recipient Postal Code
K1N 6N5
Recipient Province or Territory
ON
Recipient Type
S
Reference Number
172-2021-2022-Q4-988469